Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.

What symbol and exchange does Kairos Pharma Ltd. shares trade?

Kairos Pharma Ltd. trades on the AMEX stock market under the symbol KAPA.

What is Kairos Pharma Ltd. stock price doing today?

As of November 3, 2026, KAPA stock price climbed to $0.50 with 190,843 million shares trading.

What is Kairos Pharma Ltd.'s Beta?

KAPA has a beta of 3.29, meaning it tends to be more sensitive to market movements. KAPA has a correlation of 0.14 to the broad based SPY ETF.

How much is Kairos Pharma Ltd. worth?

KAPA has a market cap of $1.71 million. This is considered a Sub-Micro Cap stock.

What are the top ETFs holding Kairos Pharma Ltd.?

The top ETF exchange traded funds that KAPA belongs to (by Net Assets): VXF.

Is Kairos Pharma Ltd. (KAPA) a good investment?

KAPA has underperformed the market in the last year with a price return of -93.6% while the SPY ETF gained +11.7%. KAPA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -76.4% and -11.4%, respectively, while the SPY returned +1.2% and -1.6%, respectively.

What are the support and resistance levels for Kairos Pharma Ltd. (KAPA)?

KAPA support price is $.43 and resistance is $.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KAPA shares will trade within this expected range on the day.